// App-Quantinova.ai

298 : Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients

Researchers

Presenter

  • F Javier Carmona

Principal Investigators

  • David Hyman

  • Gary Ulaner

  • Joe Erinjeri

  • Nancy Bouvier

  • Helen Won

  • Richard Cutler

  • Al Alani

  • Michael Berger

  • Jose Baselga

  • Maurizio Scaltriti

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Puma Biotechnology, Inc., CA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Erb-B2 Receptor Tyrosine Kinase 3

  • PI3K/AKT

Drug/Treatment

  • Trastuzumab

  • Neratinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved